<DOC>
	<DOCNO>NCT00821028</DOCNO>
	<brief_summary>To see restenosis rate superficial femoral artery atherosclerosis percutaneous technique improve use paclitaxel .</brief_summary>
	<brief_title>Local Paclitaxel Delivery SFA Disease</brief_title>
	<detailed_description>Treatment superficial femoral artery atherosclerosis percutaneous technique hinder high restenosis rate . Paclitaxel inhibit restenosis coronary artery , study suggest may effective reduce restenosis rate peripheral artery . The investigator hypothesize deliver paclitaxel irrigate catheter superior prevent restenosis .</detailed_description>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>All subject 18 80 year age symptomatic claudication ( Rutherford category 16 ) TASC II type A , B , C lesion invite participate ( 23 , 24 ) . Patients must appropriate pharmacologic therapy PAD include antiplatelet agent lipidlowering therapy . Life expectancy &lt; 1year Acute limb ischemia Anatomy amenable percutaneous revascularization Inability provide inform consent Renal insufficiency ( creatinine clearance &lt; 40mL/min calculate use CockcroftGault equation ) Prisoners Pregnant lactate woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>atherosclerosis</keyword>
	<keyword>angioplasty</keyword>
	<keyword>peripheral arterial disease</keyword>
</DOC>